

# Balaxi Pharmaceuticals Limited

To  
Listing Department,  
National Stock Exchange of India Limited.  
Exchange Plaza, Plot No C/1, G Block, Bandra Kurla Complex,  
Bandra (E), Mumbai-400051

3<sup>rd</sup> August, 2022

Stock Code: BALAXI

**Sub: Newspaper Publication**

Dear Sir/Madam,

Pursuant to Regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Newspaper clippings published on 3rd August, 2022 in Business Standard (English) and Nava Telangana (Regional(Telugu) Edition) regarding the un-audited Standalone and Consolidated financial results of the Company for the 1<sup>st</sup> quarter ended 30<sup>th</sup> June, 2022.

The above information is also available on the website of the Company at [www.balaxipharma.in](http://www.balaxipharma.in)

This is for your information and record.

Yours Faithfully,  
For Balaxi Pharmaceuticals Limited,

Chinta Shalini  
Company Secretary



**Registered Office:**

2<sup>nd</sup> Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: [info@balaxi.in](mailto:info@balaxi.in) | Website: [www.balaxipharma.in](http://www.balaxipharma.in)

Place : Mumbai  
Date : August 02, 2022

**Yugal Sikri**  
Managing Director  
DIN:07576560

# Balaxi Pharmaceuticals Limited

Registered Office: 2<sup>nd</sup> Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.  
CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

## EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2022

(Rs. in Lakhs, unless specified)

Sl. No.	Particulars	STANDALONE			CONSOLIDATED		
		Quarter ended 30/06/2022 Unaudited	Quarter ended 31/03/2022 Audited	Quarter ended 30/06/2021 Unaudited	Quarter ended 30/06/2022 Unaudited	Quarter ended 31/03/2022 Audited	Quarter ended 30/06/2021 Unaudited
1.	Total Revenue from Operations	2645.36	2064.69	2918.04	8278.49	8909.94	5833.53
2.	Net profit/(loss) for the period (before tax, exceptional and/or extraordinary items)	653.28	487.66	593.41	1664.85	1502.06	1249.11
3.	Net profit/(loss) for the period before tax (after exceptional and/or extraordinary items)	653.28	487.66	593.41	1664.85	1502.06	1249.11
4.	Net profit/(loss) for the period after tax (after exceptional and/or extraordinary items)	533.52	352.64	443.25	1414.66	1271.06	1071.37
5.	Total Comprehensive Income for the period [Comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	533.52	352.64	443.25	1655.25	1225.81	1154.63
6.	Paid-up Equity Share Capital [Face value of Rs. 10 each]	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00	1,000.00
7.	Reserves (excluding Revaluation Reserve) as per the Audited Balance Sheet of the previous year			4791.30			10316.42
8.	Earnings Per Share (of Rs.10/- each) (not annualised)						
	1. Basic (amount in Rs.)	5.34	3.53	4.43	14.15	12.71	10.71
	2. Diluted (amount in Rs.)	5.34	3.53	4.43	14.15	12.71	10.71

**Notes:**

- The above is an extract of the detailed format of Financial Results for the quarter ended 30th June, 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Unaudited Standalone and Consolidated Financial Results is available on the website of the Stock Exchange at [www.nseindia.com](http://www.nseindia.com) (NSE) and on the Company's website at [www.balaxipharma.in](http://www.balaxipharma.in).
- The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 2nd August, 2022 and have been subjected to Limited Review by the Statutory Auditors of the Company. The said Financial Results are prepared in accordance with the Indian Accounting Standards (IndAS) as prescribed under Section 133 of the Companies Act, 2013.

For and on behalf of Board of Directors,  
**Balaxi Pharmaceuticals Limited**

Place: Hyderabad  
Date: 2nd August, 2022

**Ashish Maheshwari**  
Managing Director

**Jay**  
SPEAKS



To book your copy, call 022 41

